Description:
A drug used to treat adults with stage I, stage II, or stage III cutaneous T-cell lymphoma that came back or did not get better after treatment with at least one other systemic therapy. It is also being studied in the treatment of other types of cancer. Denileukin diftitox is made by combining interleukin-2 (IL-2) with a bacterial toxin. The IL-2 part of the drug attaches to the cancer cells and the toxin kills them. Denileukin diftitox is a type of immunotoxin and a type of recombinant fusion protein. Also called Lymphir.
